Identification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to Crizotinib

ALK receptor tyrosine kinase gene (ALK) fusion is an important driving oncogene in NSCLC, and echinoderm microtubule associated protein like 4 gene (EML4)-ALK fusion is the most prevalent type. With the rapid development and popularity of tumor genomic sequencing, more and more uncommon ALK fusion partners have been discovered, including kinesin family member 5B gene (KIF5B), baculoviral IAP repeat containing 6 gene (BIRC6), and striatin gene (STRN). However, two ALK fusions detected simultaneously in one patient with NSCLC is still rare. Here we present a novel EML4-ALK, B-cell CLL/lymphoma 11A gene (BCL11A)-ALK double-fusion variant in a patient with lung adenocarcinoma who responded well to crizotinib and describe the dynamic change in these two ALK fusions after crizotinib treatment. READ ARTICLE

Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.01.032

Authors: Bao-Dong Qin, Xiao-Dong Jiao, Ke Liu, Ying Wu, Yuan-Sheng Zang

EditorialKirk SmithJune 1, 2019EML4-ALK, BCL11A-ALK, Double-Fusion Variant, Lung Adenocarcinoma, Next-Generation Sequencing, Crizotinib

SRBD1-ALK, a Novel ALK Fusion Gene Identified in an Adenocarcinoma Patient by Next-Generation Sequencing

... Here, we report a case of adenocarcinoma harboring a novel S1 RNA binding domain 1 (SRBD1)–ALK fusion gene identified accidentally during routine molecular profiling by next-generation sequencing... Without any other oncogenic mutation detected, we speculate that the novel SRBD1-ALK fusion served as a driver mutation of the patient’s disease. And ALK TKIs might be effective in the treatment of tumors with this new fusion gene. READ ARTICLE

Journal of Thoracic Oncology DOI:10.1016/j.jtho.2018.11.027

Authors: Xue Hou, Huamin Xu, Likun Chen

Case StudyKirk SmithApril 1, 2019SRBD1-ALK, ALK Fusion, Adenocarcinoma, Next-Generation Sequencing